Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma

on May 9 | in Headlines, News, World News | by | with No Comments

water droplet smlA PROSPECTIVE RANDOMISED Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation by Ruth Pettengell et al

Purpose The objective of this randomized trial was to assess the efficacy and safety of rituximab as in vivo purging before transplantation and as maintenance treatment immediately after high-dose chemotherapy and autologous stem-cell transplantation (HDC-ASCT) in patients with relapsed follicular lymphoma (FL).

Patients and Methods Patients with relapsed FL who achieved either complete or very good partial remission with salvage chemotherapy were randomly assigned using a factorial design to rituximab purging (P+; 375 mg/m2 once per week for 4 weeks) or observation (NP) before HDC-ASCT and to maintenance rituximab (M+; 375 mg/m2 once every 2 months for four infusions) or observation (NM)…Read more

Source: www.jco.ascopubs.org



Pin It

Related Posts

Comments are closed.

« »

Scroll to top